Book 2016

Managing the Drug Discovery Process: How to Make It More Efficient and Cost-Effective

Managing the Drug Discovery Process: How to Make It More Efficient and Cost-Effective
Journal · pp. 1-506
Abstract

Managing the Drug Discovery Process: How to Make It More Efficient and Cost-Effective thoroughly examines the current state of pharmaceutical research and development by providing chemistry-based perspectives on biomedical research, drug hunting and innovation. The book also considers the interplay of stakeholders, consumers, and the drug firm with attendant factors, including those that are technical, legal, economic, demographic, political, social, ecological, and infrastructural. Since drug research can be a high-risk, high-payoff industry, it is important to researchers to effectively and strategically manage the drug discovery process. This book takes a closer look at increasing pre-approval costs for new drugs and examines not only why these increases occur, but also how they can be overcome to ensure a robust pharmacoeconomic future. Written in an engaging manner and including memorable insights, this book is aimed at redirecting the drug discovery process to make it more efficient and cost-effective in order to achieve the goal of saving countless more lives through science. A valuable and compelling resource, this is a must-read for all students and researchers in academia and the pharmaceutical industry. Considers drug discovery in multiple R&D venues, including big pharma, large biotech, start-up ventures, academia, and nonprofit research institutes Analyzes the organization of pharmaceutical R&D, taking into account human resources considerations like recruitment and configuration, management of discovery and development processes, and the coordination of internal research within, and beyond, the organization, including outsourced work Presents a consistent, well-connected, and logical dialogue that readers will find both comprehensive and approachable. © 2017 Elsevier Ltd. All rights reserved.

Keywords

Author Keywords

Not provided

Index Keywords

Author Affiliations
Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, United States
Ash Stevens Inc., Detroit, MI, United States
Department of Chemistry, Wayne State University, Detroit, MI, United States
Funding & Acknowledgements
No funding information
References 10 References
1 Balaram, Padmanabhan, Drug discovery: Myth and reality, Current Science, 87, 7, pp. 847-848, (2004)
2 Creative Destruction Why Companies that are Built to Last Underperform the Market and how to Successfully Transform Them, (2001)
3 Irwin, Michael H., Epigenetic Treatment of Neurodegenerative Disorders: Alzheimer and Parkinson Diseases, Drug Development Research, 77, 3, pp. 109-123, (2016)
4 Kornberg, Arthur, The Two Cultures: Chemistry and Biology, Biochemistry, 26, 22, pp. 6888-6891, (1987)
5 Moos, Walter H., Microbiota and Neurological Disorders: A Gut Feeling, BioResearch Open Access, 5, 1, pp. 137-145, (2016)
6 Moos, Walter H., Epigenetic Treatment of Neuropsychiatric Disorders: Autism and Schizophrenia, Drug Development Research, 77, 2, pp. 53-72, (2016)
7 Śmietana, Katarzyna, Trends in clinical success rates, Nature Reviews Drug Discovery, 15, 6, pp. 379-380, (2016)
8 Sneader, Walter E., Drug Discovery: A History, Drug Discovery: A History, pp. 1-468, (2006)
9 Their Points of View, (1904)
10 Repetitive flaws, Nature, 529, 7586, (2016)
Quick Actions
Citation Metrics
5
Times Cited (Scopus)

References 10
Document Identifiers
  • EID 2-s2.0-85009653924
  • Language English